Novel therapeutics in hypertriglyceridemia
Authors:
- Steven E. GrynSGSteven E. Gryn
- Robert A. HegeleRHRobert A. Hegele
- 1 December 2015
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 26 (6) , 484-491
Abstract
We provide an overview of recent advances in the therapy of hypertriglyceridemia, focusing on several new therapies with potential for treating of familial chylomicronemia, other forms of hypertriglyceridemia, and for triglyceride-lowering in patients with other lipid disorders. Newer triglyceride-lowering modalities under evaluation include gene therapy for lipoprotein lipase deficiency (alipogene tiparvovec), and antisense oligonucleotides against mRNA for apolipoproteins B (mipomersen) and C3 (volanesorsen, ISIS 304801). Other potential therapies include small molecule inhibitors of microsomal triglyceride transfer protein (lomitapide) and diacylglycerol acyltransferase-1 (pradigastat), and a monoclonal antibody against angiopoietin-like protein 3 (REGN1500). There is also renewed interest in omega-3 fatty acids, and in developing potent and selective agonists of peroxisome proliferator-activated receptors. Several promising triglyceride-lowering therapies are at various stages of development; a few are even available in some markets. Although existing data suggest good biochemical efficacy, data on long-term clinical outcomes are still limited. For some therapies, cost will be an important consideration, and use will likely be restricted to orphan indications, for example very severe cases of hypertriglyceridemia as seen in familial chylomicronemia syndrome, although some therapies could theoretically be more broadly used one day for cardiovascular disease prevention.Keywords
This publication has 56 references indexed in Scilit:
- Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular DiseaseCardiology Clinics, 2015
- Chylomicronaemia—current diagnosis and future therapiesNature Reviews Endocrinology, 2015
- Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarctionNature, 2014
- The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and managementThe Lancet Diabetes & Endocrinology, 2014
- Loss-of-Function Mutations inAPOC3and Risk of Ischemic Vascular DiseaseNew England Journal of Medicine, 2014
- Loss-of-Function Mutations inAPOC3,Triglycerides, and Coronary DiseaseNew England Journal of Medicine, 2014
- Common variants associated with plasma triglycerides and risk for coronary artery diseaseNature Genetics, 2013
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation studyThe Lancet, 2012
- Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studiesThe Lancet, 2010
- Major Lipids, Apolipoproteins, and Risk of Vascular DiseaseJAMA, 2009